Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect.

ABSTRACT: We investigated the effect of angiotensin receptor neprilysin inhibitor (ARNI) on glycemic control in Korean patients. This retrospective cohort study was conducted at a single tertiary hospital. We compared the HbA_1c level reduction between the ARNI and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in chronic heart failure patients with diabetes. We also examined whether the target HbA_1c level was reached and the time to start insulin between the two groups. Over the study period, ARNI did not significantly lower the HbA_1c level after adjusting confounding factors compared to ACEIs or ARBs. However, as a result of a simple comparison using Mann-Whitney U test, ARNI group showed significant decrease in HbA₁

SUBMITTER: Kim H 

PROVIDER: S-EPMC9188559 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature